37 research outputs found
ΠΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΎΠ±Π·ΠΎΡ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎ-ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΠΏΠΎΡΠΊΠΈ ΠΈ ΠΌΠΎΡΠ΅Π²ΠΎΠ³ΠΎ ΠΏΡΠ·ΡΡΡ
Background. In recent years, an increase in the incidence of multiple primary malignancies has been observed. Multiple primary malignancies are an independent occurrence and development of two or more neoplasms of different histological origin in one patient.Aim. To evaluate epidemiological, clinical and morphological aspects of primary multiple malignant neoplasms of the prostate, kidney, and bladder.Materials and methods. Data analysis of the work report of the Saratov region oncological service in 2019, presented by the Regional Clinical Oncological Dispensary, patient case histories in the archive of the medical information system was performed.We performed a comparative analysis of the literature sources and data we obtained based to the following criteria: topographic anatomical combination of tumor locations, distribution of tumor combinations depending on time of occurrence (synchronous, metachronous), dynamics of urogenital multiple primary malignancies diagnosis in 2012-2019, distribution by gender and age, combination of stages of tumor process in both tumors, distribution by combination of histological types.Results. Between 2012 and 2019, 783 cases of multiple primary tumors with lesions in the urogenital system were identified. We studied 186 cases with a combination of two malignant neoplasms in the prostate, kidney, and bladder. Tumors developed synchronously in 36 % of patients, metachronously in 64 %. Mean patient age was 75 years. Half of the cases were in the group of localized stages - 90 (48.4 %), with the most common combination of TI-TII stages observed in 46 (24.7 %) cases. Combinations of acinar adenocarcinoma of the prostate with urothelial carcinoma of the bladder (34.7 %), clear cell renal carcinoma (27.8 %), papillary urothelial carcinoma of the bladder (12.5 %) were the most common according to histological diagnosis of primary multiple tumors of the urogenital system.Conclusion. Over the recent years we can observe a steady growth of diagnosable urogenital multiple primary malignancies. Morphological verification of the tumor and revelation of the most frequent histological types allows to assume the presence of the common mechanisms of development and the influence of tumor microenvironment on the growth of both tumors in a multiple primary malignancies pair.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π³ΠΎΠ΄Ρ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΡΡΠΎΡΡ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎ-ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ. ΠΠ΅ΡΠ²ΠΈΡΠ½ΠΎ-ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ - Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΠΎΠ΅ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΠ΅ ΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ Ρ 1 Π±ΠΎΠ»ΡΠ½ΠΎΠ³ΠΎ 2 ΠΈΠ»ΠΈ Π±ΠΎΠ»Π΅Π΅ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΈΠΌΠ΅ΡΡ ΡΠ°Π·Π½ΠΎΠ΅ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΏΡΠΎΠΈΡΡ
ΠΎΠΆΠ΄Π΅Π½ΠΈΠ΅.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ - ΠΎΡΠ΅Π½ΠΊΠ° ΡΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π°ΡΠΏΠ΅ΠΊΡΠΎΠ² ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎ-ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΠΏΠΎΡΠΊΠΈ ΠΈ ΠΌΠΎΡΠ΅Π²ΠΎΠ³ΠΎ ΠΏΡΠ·ΡΡΡ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· Π΄Π°Π½Π½ΡΡ
Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΎΡΡΠ΅ΡΠ° ΠΏΠΎ ΠΈΡΠΎΠ³Π°ΠΌ ΡΠ°Π±ΠΎΡΡ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ»ΡΠΆΠ±Ρ Π‘Π°ΡΠ°ΡΠΎΠ²ΡΠΊΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ Π² 2019 Π³., ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΡΠΌ ΠΠ±Π»Π°ΡΡΠ½ΡΠΌ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π΄ΠΈΡΠΏΠ°Π½ΡΠ΅ΡΠΎΠΌ, ΠΈΡΡΠΎΡΠΈΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ, Π½Π°Ρ
ΠΎΠ΄ΡΡΠΈΡ
ΡΡ Π² Π°ΡΡ
ΠΈΠ²Π΅ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ.ΠΡΠΏΠΎΠ»Π½Π΅Π½ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠΎΠ² Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ
Π½Π°ΠΌΠΈ Π΄Π°Π½Π½ΡΡ
ΠΏΠΎ ΡΠ»Π΅Π΄ΡΡΡΠΈΠΌ ΠΊΡΠΈΡΠ΅ΡΠΈΡΠΌ: ΡΠΎΠΏΠΎΠ³ΡΠ°ΡΠΎ-Π°Π½Π°ΡΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΠΉ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ, ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΡ (ΡΠΈΠ½Ρ
ΡΠΎΠ½Π½ΠΎΠ΅, ΠΌΠ΅ΡΠ°Ρ
ΡΠΎΠ½Π½ΠΎΠ΅), Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ° Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎ-ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ ΠΌΠΎΡΠ΅ΠΏΠΎΠ»ΠΎΠ²ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ Π·Π° 2012-2019 Π³Π³., ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎ ΠΏΠΎΠ»Ρ ΠΈ Π²ΠΎΠ·ΡΠ°ΡΡΡ, ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ ΡΡΠ°Π΄ΠΈΠΉ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° Π² ΠΎΠ±Π΅ΠΈΡ
ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ
, ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΡ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠΏΠΎΠ².Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ° ΠΏΠ΅ΡΠΈΠΎΠ΄ 2012-2019 Π³Π³. Π²ΡΡΠ²Π»Π΅Π½ΠΎ 783 ΡΠ»ΡΡΠ°Ρ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎ-ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ Ρ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΎΡΠ³Π°Π½ΠΎΠ² ΠΌΠΎΡΠ΅ΠΏΠΎΠ»ΠΎΠ²ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ. ΠΠ·ΡΡΠ΅Π½ΠΎ 186 ΡΠ»ΡΡΠ°Π΅Π² Ρ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ 2 Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ Π² ΡΠ»Π΅Π΄ΡΡΡΠΈΡ
ΠΎΡΠ³Π°Π½Π°Ρ
: ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Π΅, ΠΏΠΎΡΠΊΠ΅, ΠΌΠΎΡΠ΅Π²ΠΎΠΌ ΠΏΡΠ·ΡΡΠ΅. ΠΠΏΡΡ
ΠΎΠ»ΠΈ ΡΠ°Π·Π²ΠΈΠ²Π°Π»ΠΈΡΡ ΡΠΈΠ½Ρ
ΡΠΎΠ½Π½ΠΎ Ρ 36 % ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΌΠ΅ΡΠ°Ρ
ΡΠΎΠ½Π½ΠΎ - Ρ 64 %. Π‘ΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΡΡΠ°Π²ΠΈΠ» 75 Π»Π΅Ρ. ΠΠΎΠ»ΠΎΠ²ΠΈΠ½Π° ΡΠ»ΡΡΠ°Π΅Π² ΠΎΡΠ½ΠΎΡΠΈΠ»Π°ΡΡ ΠΊ Π³ΡΡΠΏΠΏΠ΅ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΡ
ΡΡΠ°Π΄ΠΈΠΉ - 90 (48,4 %), ΠΏΡΠΈΡΠ΅ΠΌ ΡΠ°ΠΌΡΠΌ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠΌ Π±ΡΠ»ΠΎ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ ΡΡΠ°Π΄ΠΈΠΈ TI-TII - 46 (24,7 %). ΠΡΠΈ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎ-ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ ΠΌΠΎΡΠ΅ΠΏΠΎΠ»ΠΎΠ²ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΠΏΡΠ΅ΠΎΠ±Π»Π°Π΄Π°Π»ΠΈ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΡ Π°ΡΠΈΠ½Π°ΡΠ½ΠΎΠΉ Π°Π΄Π΅Π½ΠΎΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Ρ ΡΡΠΎΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠΎΠΉ ΠΌΠΎΡΠ΅Π²ΠΎΠ³ΠΎ ΠΏΡΠ·ΡΡΡ (34,7 %), ΡΠ²Π΅ΡΠ»ΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΠΎΡΠΊΠΈ (27,8 %), ΠΏΠ°ΠΏΠΈΠ»Π»ΡΡΠ½ΠΎΠΉ ΡΡΠΎΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠΎΠΉ ΠΌΠΎΡΠ΅Π²ΠΎΠ³ΠΎ ΠΏΡΠ·ΡΡΡ (12,5 %).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ° ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π³ΠΎΠ΄Ρ Π½Π°Π±Π»ΡΠ΄Π°Π΅ΡΡΡ ΠΏΠΎΡΡΠΎΡΠ½Π½ΡΠΉ ΡΠΎΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΡΠ΅ΠΌΡΡ
ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎ-ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π·Π»ΠΎΠΊΠ°-ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ ΠΌΠΎΡΠ΅ΠΏΠΎΠ»ΠΎΠ²ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ Π²Π΅ΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΈ Π²ΡΡΠ²Π»Π΅Π½ΠΈΠ΅ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΠΎ Π²ΡΡΡΠ΅ΡΠ°ΡΡΠΈΡ
ΡΡ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠΏΠΎΠ² ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠΈΡΡ Π½Π°Π»ΠΈΡΠΈΠ΅ ΠΎΠ±ΡΠΈΡ
ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠΎΠ² ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΈ Π²Π»ΠΈΡΠ½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΠΌΠΈΠΊΡΠΎΠΎΠΊΡΡΠΆΠ΅Π½ΠΈΡ Π½Π° ΡΠΎΡΡ ΠΎΠ±Π΅ΠΈΡ
ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ ΠΈΠ· ΠΏΠ°ΡΡ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎ-ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ
Photothermal and photodynamic therapy of tumors with plasmonic nanoparticles: challenges and prospects
Cancer remains one of the leading causes of death in the world. For a number of neo-plasms, the efficiency of conventional chemo-and radiation therapies is insufficient because of drug resistance and marked toxicity. Plasmonic photothermal therapy (PPT) using local hyperthermia induced by gold nanoparticles (AuNPs) has recently been extensively explored in tumor treatment. However, despite attractive promises, the current PPT status is limited by laboratory experiments, academic papers, and only a few preclinical studies. Unfortunately, most nanoformulations still share a similar fate: great laboratory promises and fair preclinical trials. This review discusses the current challenges and prospects of plasmonic nanomedicine based on PPT and photodynamic therapy (PDT). We start with consideration of the fundamental principles underlying plasmonic properties of AuNPs to tune their plasmon resonance for the desired NIR-I, NIR-2, and SWIR optical windows. The basic principles for simulation of optical cross-sections and plasmonic heating under CW and pulsed irradiation are discussed. Then, we consider the state-of-the-art methods for wet chemical synthesis of the most popular PPPT AuNPs such as silica/gold nanoshells, Au nanostars, nanorods, and nanocages. The photothermal efficiencies of these nanoparticles are compared, and their applications to current nanomedicine are shortly discussed. In a separate section, we discuss the fabrication of gold and other nanoparticles by the pulsed laser ablation in liquid method. The second part of the review is devoted to our recent experimental results on laser-activated interaction of AuNPs with tumor and healthy tissues and current achievements of other research groups in this application area. The unresolved issues of PPT are the significant accumulation of AuNPs in the organs of the mononuclear phagocyte system, causing potential toxic effects of nanoparticles, and the possibility of tumor recurrence due to the presence of survived tumor cells. The prospective ways of solving these problems are discussed, including developing combined antitumor therapy based on combined PPT and PDT. In the conclusion section, we summarize the most urgent needs of current PPT-based nanomedicine
The assessment of effectiveness of plasmonic resonance photothermal therapy in tumor-bearing rats after multiple intravenous administration of gold nanorods
To assess the effectiveness of plasmonic photothermal therapy (PPT) multiple intravenous strategy of gold nanorods (GNRs) administration was used before laser exposure. The model of alveolar liver cancer PC-1 was used in male outbred albino rats, which were intravenously administrated by single and multiple injections of GNRs and then were treated by PPT. The gold dosage was 400 ΞΌg (single injection group), 800 ΞΌg (double injection group), 1200 ΞΌg (triple injection group), and absorption maximum of gold nanorods suspension was at the wavelength of 808 nm. 24 hours after last injection the tumors were irradiated by the 808-nm diode laser during 15 min at power density 2.3 W/cm2. Temperature control of the tumor heating was provided by IR imager. 24 hours after the PPT the half of animals from each group was withdrawn from the experiments and the sampling tumor tissue for morphological study was performed. In survived animals the growth of tumors was evaluated during 21 days after the PPT. The antitumor effects of PPT after triple intravenous injection were comparable with those obtained at direct intratumoral administration of similar total dose of GNRs. The effectiveness of PPT depended on gold accumulation in tumor, probably, due to sufficient vascularizTation of tumor tissue
The morphological changes in transplanted tumors of rats at plasmonic photothermal therapy
The aim of work was to study the morphological changes in transplanted liver tumors of rats after plasmonic photothermal therapy (PPTT). The gold nanorods functionalized with thiolated polyethylene glycol were injected intravenously to rats with transplanted liver cancer PC-1. A day after injection the tumors were irradiated by the infrared 808-nm diode laser. The withdrawal of the animals from the experiment and sampling of tumor tissue for morphological study were performed 24 hours after the laser exposure. The standard histological and immunohistochemical staining with antibodies to proliferation marker Ki-67 and apoptosis marker BAX were used for morphological study of transplanted tumors. The plasmonic photothermal therapy had pronounced damaging effect in rats with transplanted liver tumors expressed in degenerative and necrotic changes in the tumor cells. The decrease of proliferation marker Ki-67 and increase of expression of apoptosis marker BAX were observed in tumor cells after PPTT
The effects of prolonged oral administration of gold nanoparticles on the morphology of hematopoietic and lymphoid organs
Currently, the usage of gold nanoparticles as photosensitizers and immunomodulators for plasmonic photothermal therapy has attracted a great attention of researches and end-users. In our work, the influence of prolonged peroral administration of gold nanoparticles (GNPs) with different sizes on the morphological changes of hematopoietic and lymphoid organs was investigated. The 24 white outbred male rats weighing 180-220 g were randomly divided into groups and administered orally for 30 days the suspension of gold nanospheres with diameters of 2, 15 and 50 nm at a dosage of 190 ΞΌg/kg of animal body weight. To prevent GNPs aggregation in a tissue and enhance biocompatibility, they were functionalized with thiolated polyethylene glycol. The withdrawal of the animals from the experiment and sampling of spleen, lymph nodes and bone marrow tissues for morphological study were performed a day after the last administration. In the spleen the boundary between the red and white pulp was not clearly differ in all experimental groups, lymphoid follicles were significantly increased in size, containing bright germinative centers represented by large blast cells. The stimulation of lymphocyte and myelocytic series of hematopoiesis was recorded at morphological study of the bone marrow. The number of immunoblasts and large lymphocytes was increased in all structural zones of lymph nodes. The more pronounced changes were found in the group with administration of 15 nm nanoparticles. Thus, the morphological changes of cellular components of hematopoietic organs have size-dependent character and indicate the activation of the migration, proliferation and differentiation of immune cells after prolonged oral administration of GNPs
The inflammation markers in serum of tumor-bearing rats after plasmonic photothermal therapy
We report on plasmonic photothermal therapy of rats with inoculated cholangiocarcinoma through the intratumoral injection of PEG-coated gold nanorods followed by CW laser light irradiation. The length and diameter of gold nanorods were 41Β±8 nm and 10Β±2 nm, respectively; the particle mass-volume concentration was 400 ΞΌg/mL, which corresponds to the optical density of 20 at the wavelength 808 nm. The tumor-bearing rats were randomly divided into three groups: (1) without any treatment (control); (2) with only laser irradiation of tumor; (3) with intratumoral administration of gold nanorods and laser irradiation of tumors. An hour before laser irradiation, the animals were injected intratumorally with gold nanorod solutions in the amount of 30% of the tumor volume. The infrared 808-nm laser with power density of 2.3 W/cm2 was used for plasmonic photothermal therapy (PTT). The withdraw of animals from the experiment was performed 24 h after laser exposure. The content of lipid peroxidation products and molecular markers of inflammation (TNF-Ξ±, IGF-1, VEGF-C) was determined by ELISA test in serum of rats. The standard histological techniques with hematoxylin and eosin staining were used for morphological examination of tumor tissues. It was revealed that the significant necrotic changes were noted in tumor tissue after plasmonic photothermal therapy, which were accompanied by formation of inflammatory reaction with release of proinflammatory cytokines and lipid peroxidation products into the bloodstream
Liposomes loaded with hydrophilic magnetite nanoparticles: Preparation and application as contrast agents for magnetic resonance imaging
Β© 2015 Elsevier B.V.. Magnetic fluid-loaded liposomes (MFLs) were fabricated using magnetite nanoparticles (MNPs) and natural phospholipids via the thin film hydration method followed by extrusion. The size distribution and composition of MFLs were studied using dynamic light scattering and spectrophotometry. The effective ranges of magnetite concentration in MNPs hydrosol and MFLs for contrasting at both T2 and T1 relaxation were determined. On T2 weighted images, the MFLs effectively increased the contrast if compared with MNPs hydrosol, while on T1 weighted images, MNPs hydrosol contrasting was more efficient than that of MFLs. In vivo magnetic resonance imaging (MRI) contrasting properties of MFLs and their effects on tumor and normal tissues morphology, were investigated in rats with transplanted renal cell carcinoma upon intratumoral administration of MFLs. No significant morphological changes in rat internal organs upon intratumoral injection of MFLs were detected, suggesting that the liposomes are relatively safe and can be used as the potential contrasting agents for MRI
ΠΠΠ’ΠΠΠΠ Π€ΠΠ Π ΠΠΠ ΠΠ ΠΠΠ‘Π’ΠΠ’ΠΠΠ¬ΠΠΠ ΠΠΠΠΠΠ« ΠΠ Π ΠΠΠ§ΠΠΠΠ ΠΠ«Π‘ΠΠΠΠΠΠ’ΠΠΠ‘ΠΠΠΠ«Π Π‘Π€ΠΠΠ£Π‘ΠΠ ΠΠΠΠΠΠ«Π Π£ΠΠ¬Π’Π ΠΠΠΠ£ΠΠΠ (HIFU)
The purpose of the study was to evaluate the efficiency of prostate cancer (PC) treatment using high-intensity focused ultrasound (HIFU) on the basis of morphometric and immunohistochemical (IHC) analyses of postoperative prostate biopsy specimens. The study subjects were 40 patients with localized and locally advanced PC. The postoperative morphological analysis was made on the basis of standard hematoxylineosin staining and morphometric and IHC studies using the following antibodies: PCNA, Bcl-2, AMACR, Π-cadherin, and ANDR (Dako). Pre- and post-HIFU therapy histological examination of the routinely hematoxylin-eosin-stained specimens showed that the therapeutic pathomorphism of the tumor corresponded to grades III and IV. It was established that the IHC study should be used as an additional crite-rion for the efficiency of PC therapy after HIFU ablation. In spite of positive clinical, laboratory, instrumental, and objective changes, the patients with high AMACR and Bcl-2 levels and decreased Π-cadherin expression may be considered as a group at risk for prolonged malignant growth or recurrent PC.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ (Π ΠΠ) Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π²ΡΡΠΎΠΊΠΎΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΡΠΎΠΊΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ»ΡΡΡΠ°Π·Π²ΡΠΊΠ° (HIFU) Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΌΠΎΡΡΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ (ΠΠΠ₯) Π°Π½Π°Π»ΠΈΠ·Π° ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
Π±ΠΈΠΎΠΏΡΠ°ΡΠΎΠ² ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΠ±ΡΠ΅ΠΊΡΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ²ΠΈΠ»ΠΈΡΡ 40 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΌ ΠΈ ΠΌΠ΅ΡΡΠ½ΠΎ-ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠΌ Π ΠΠ. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΏΠΎΡΠ»Π΅ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠΉ ΠΎΠΊΡΠ°ΡΠΊΠΈ ΡΡΠ΅Π·ΠΎΠ² Π³Π΅ΠΌΠ°ΡΠΎΠΊΡΠΈΠ»ΠΈΠ½-ΡΠΎΠ·ΠΈΠ½ΠΎΠΌ, ΠΌΠΎΡΡΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈ ΠΠΠ₯-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠ»Π΅Π΄ΡΡΡΠΈΡ
Π°Π½ΡΠΈΡΠ΅Π»: PCNA, Bcl-2, AMACR, Π-ΠΊΠ°Π΄Π³Π΅ΡΠΈΠ½, ANDR (Dako). ΠΡΠΈ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠΈ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π° Π΄ΠΎ ΠΈ ΠΏΠΎΡΠ»Π΅ HIFU-ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΡΠΈ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠΉ ΠΎΠΊΡΠ°ΡΠΊΠ΅ Π³Π΅ΠΌΠ°ΡΠΎΠΊΡΠΈΠ»ΠΈΠ½-ΡΠΎΠ·ΠΈΠ½ΠΎΠΌ Π»Π΅ΡΠ΅Π±Π½ΡΠΉ ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ· ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΎΠ²Π°Π» III ΠΈ IV ΡΡΠ΅ΠΏΠ΅Π½ΡΠΌ. ΠΡΠ»ΠΎ Π²ΡΡΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π²Β ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΡΠΈΡΠ΅ΡΠΈΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Π ΠΠ ΠΏΠΎΡΠ»Π΅ HIFU Π°Π±Π»Π°ΡΠΈΠΈ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΠΠ₯-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Π²ΡΡΠΎΠΊΠΈΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ AMACR, Bcl-2 ΠΈ ΡΠ½ΠΈΠΆΠ΅Π½Π½ΠΎΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ Π-ΠΊΠ°Π΄Π³Π΅ΡΠΈΠ½Π°, Π½Π΅ΡΠΌΠΎΡΡΡ Π½Π° ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΡ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΡ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
, ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΡ
ΠΈ ΠΎΠ±ΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ, ΠΌΠΎΠ³ΡΡ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡΡΡ ΠΊΠ°ΠΊ Π³ΡΡΠΏΠΏΠ° ΡΠΈΡΠΊΠ° ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠ΅Π½Π½ΠΎΠ³ΠΎ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΡΠΎΡΡΠ° Π»ΠΈΠ±ΠΎ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π° Π ΠΠ
Π’ΠΊΠ°Π½Π΅Π²Π°Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π°ΡΡΠΎΡΠ°Π³ΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠΊΠ΅ΡΠ° LC3B ΠΊΠ°ΠΊ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΠΉ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅Ρ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π° ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΠΏΠΎΡΠ»Π΅ Π»Π΅ΡΠ΅Π½ΠΈΡ Π²ΡΡΠΎΠΊΠΎΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΡΠΌ ΡΡΠΎΠΊΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ»ΡΡΡΠ°Π·Π²ΡΠΊΠΎΠΌ (ΠΏΠΈΠ»ΠΎΡΠ½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅)
Background. The role of autophagy markers in prostate tumor recurrence has not been sufficiently investigated. We hypothesized that autophagy activation may be one mechanism by which prostate cancer cells survive exposure to high-intensity focused ultrasound (HIFU).Aim. To compare tissue expression of autophagic LC3B marker in prostate biopsies before and after treatment of localized prostate cancer by HIFU ablation.Materials and methods. 45 patients with localized morphologically confirmed prostate cancer were examined: group 1 β 25 patients of 65.6 Β± 8.4 years without signs of recurrence or progression of the disease; group 2 β 20 patients of 67.5 Β± 7.9 years with tumor recurrence proven during morphological examination. Immunohistochemical examination was performed by streptavidin-biotin method. In all cases, Anti-LC3B antibody ab48394 was used. The reaction results were quantified using the Histochemical score (Hs) system.Results. Prior to treatment, all patients of group 1 showed moderate cytoplasmic expression (Hs = 111 [111; 115]) of antibodies against LC3B in prostate adenocarcinoma cells, 5 % of patients β weak cytoplasmic expression in muscle connective stromal cells (Hs = 47 [43; 50]), 10 % of patients β weak positive LC3B reaction in the vessel wall (Hs = 28 [20; 35]). After treatment, the expression of LC3B in adenocarcinoma cells became negative, in the cytoplasm of muscle connective stromal cells weak (Hs = 75 [67.5; 80.0]), in the endothelium of the vascular wall even weaker (Hs = 55 [45.5; 60.0]) (p <0.001). Prior to treatment in group 2, LC3B expression in tumor tissue was moderate in 89 % of patients (Hs = 151.5 [137.5; 160.0]), weak in muscle connective stromal cells in 12 % of patients (Hs = 44 [35; 51.5]), and weak in the vascular wall in 5 % of patients (Hs = 30 [25; 35]). After treatment, LC3B expression in adenocarcinoma cells became pronounced (Hs = 260 [250; 285]), in muscle connective stromal cells β moderate (Hs = 118 [100; 130]), in the vascular wall β weak (Hs = 45 [30; 55]) (p <0.001). There was a significant correlation between tumor recurrence and LC3B overexpression (r = 0.51; p <0.001).Conclusion. The development of prostate cancer recurrence is associated with increased expression of autophagic LC3B protein. Increased LC3B expression, which is interpreted as evidence of autophagy activation and correlates with the risk of disease progression, is used by the tumor as an oncogenic advantage.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π ΠΎΠ»Ρ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π°ΡΡΠΎΡΠ°Π³ΠΈΠΈ ΠΏΡΠΈ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π΅ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π°. ΠΡ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠΈΠ»ΠΈ, ΡΡΠΎ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΡ Π°ΡΡΠΎΡΠ°Π³ΠΈΠΈ ΠΌΠΎΠΆΠ΅Ρ ΡΠ²Π»ΡΡΡΡΡ ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠΎΠ², Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ ΠΊΠ»Π΅ΡΠΊΠΈ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Π²ΡΠΆΠΈΠ²Π°ΡΡ ΠΏΠΎΡΠ»Π΅ Π²ΠΎΠ·Π΄Π΅ΠΉΡΡΠ²ΠΈΡ Π²ΡΡΠΎΠΊΠΎΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΡΠΌ ΡΡΠΎΠΊΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ»ΡΡΡΠ°Π·Π²ΡΠΊΠΎΠΌ (HIFU).Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΡΡΠ°Π²Π½ΠΈΡΡ ΡΠΊΠ°Π½Π΅Π²ΡΡ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π°ΡΡΠΎΡΠ°Π³ΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠΊΠ΅ΡΠ° LC3B Π² Π±ΠΈΠΎΠΏΡΠ°ΡΠ°Ρ
ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Π΄ΠΎ ΠΈ ΠΏΠΎΡΠ»Π΅ Π»Π΅ΡΠ΅Π½ΠΈΡ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ HIFU-Π°Π±Π»Π°ΡΠΈΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ 45 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½Π½ΡΠΌ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ: 1-Ρ Π³ΡΡΠΏΠΏΠ° β 25 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ 65,6 Β± 8,4 Π³ΠΎΠ΄Π°) Π±Π΅Π· ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π° ΠΈΠ»ΠΈ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ; 2-Ρ Π³ΡΡΠΏΠΏΠ° β 20 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ 67,5 Β± 7,9 Π³ΠΎΠ΄Π°) Ρ Π΄ΠΎΠΊΠ°Π·Π°Π½Π½ΡΠΌ ΠΏΡΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΎΠΌ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ. ΠΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΡΡΡΠ΅ΠΏΡΠ°Π²ΠΈΠ΄ΠΈΠ½-Π±ΠΈΠΎΡΠΈΠ½ΠΎΠ²ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ. ΠΠΎ Π²ΡΠ΅Ρ
ΡΠ»ΡΡΠ°ΡΡ
ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ Π°Π½ΡΠΈΡΠ΅Π»ΠΎ Anti-LC3B antibody ab48394. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ΅Π°ΠΊΡΠΈΠΈ ΠΏΠΎΠ΄ΡΡΠΈΡΡΠ²Π°Π»ΠΈ ΠΏΠΎ ΡΠΈΡΡΠ΅ΠΌΠ΅ Histochemical score (Hs).Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Ρ Π²ΡΠ΅Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² 1-ΠΉ Π³ΡΡΠΏΠΏΡ Π·Π°ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½Π° ΡΠΌΠ΅ΡΠ΅Π½Π½Π°Ρ ΡΠΈΡΠΎΠΏΠ»Π°Π·ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ (Hs = 111 [111; 115]) Π°Π½ΡΠΈΡΠ΅Π» ΠΊ LC3B Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
Π°Π΄Π΅Π½ΠΎΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, Ρ 5 % β ΡΠ»Π°Π±Π°Ρ ΡΠΈΡΠΎΠΏΠ»Π°Π·ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΌΡΡΠ΅ΡΠ½ΠΎ-ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΠΊΠ°Π½Π½ΠΎΠΉ ΡΡΡΠΎΠΌΡ (Hs = 47 [43; 50]), Ρ 10 % β ΡΠ»Π°Π±Π°Ρ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΡΠ΅Π°ΠΊΡΠΈΡ LC3B Π² ΡΡΠ΅Π½ΠΊΠ΅ ΡΠΎΡΡΠ΄ΠΎΠ² (Hs = 28 [20; 35]). ΠΠΎΡΠ»Π΅ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ LC3B Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
Π°Π΄Π΅Π½ΠΎΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ ΡΡΠ°Π»Π° ΠΎΡΡΠΈΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ, Π² ΡΠΈΡΠΎΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΌΡΡΠ΅ΡΠ½ΠΎ-ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΠΊΠ°Π½Π½ΠΎΠΉ ΡΡΡΠΎΠΌΡ β ΡΠ»Π°Π±ΠΎΠΉ (Hs = 75 [67,5; 80,0]), Π² ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΠΈ ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΡΠ΅Π½ΠΊΠΈ β Π΅ΡΠ΅ ΡΠ»Π°Π±Π΅Π΅ (Hs = 55 [45,5; 60,0]) (Ρ <0,001). ΠΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π²ΠΎ 2-ΠΉ Π³ΡΡΠΏΠΏΠ΅ Ρ 89 % ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π²ΡΡΠ²Π»Π΅Π½Π° ΡΠΌΠ΅ΡΠ΅Π½Π½Π°Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ LC3B Π² ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ(Hs = 151,5 [137,5; 160,0]), Ρ 12 % β ΡΠ»Π°Π±Π°Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΌΡΡΠ΅ΡΠ½ΠΎ-ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΠΊΠ°Π½Π½ΠΎΠΉ ΡΡΡΠΎΠΌΡ (Hs = 44 [35; 51,5]), Ρ 5 % β ΡΠ»Π°Π±Π°Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π² ΡΡΠ΅Π½ΠΊΠ΅ ΡΠΎΡΡΠ΄ΠΎΠ² (Hs = 30 [25; 35]). ΠΠΎΡΠ»Π΅ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ LC3B Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
Π°Π΄Π΅Π½ΠΎΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ ΡΡΠ°Π»Π° Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΠΉ (Hs = 260 [250; 285]), Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΌΡΡΠ΅ΡΠ½ΠΎ-ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΠΊΠ°Π½Π½ΠΎΠΉ ΡΡΡΠΎΠΌΡ β ΡΠΌΠ΅ΡΠ΅Π½Π½ΠΎΠΉ (Hs = 118 [100; 130]), Π² ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΡΠ΅Π½ΠΊΠ΅ β ΡΠ»Π°Π±ΠΎΠΉ (Hs = 45 [30; 55]) (Ρ <0,001). ΠΠ°ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½Π° Π·Π½Π°ΡΠΈΠΌΠ°Ρ Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΡ ΠΌΠ΅ΠΆΠ΄Ρ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΎΠΌ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΈ Π³ΠΈΠΏΠ΅ΡΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ LC3B (r = 0,51; p <0,001).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π Π°Π·Π²ΠΈΡΠΈΠ΅ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π° ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΡΠ²ΡΠ·Π°Π½ΠΎ Ρ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π°ΡΡΠΎΡΠ°Π³ΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° LC3B. ΠΠΎΠ²ΡΡΠ΅Π½Π½Π°Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ LC3B, ΠΊΠΎΡΠΎΡΠ°Ρ ΠΈΠ½ΡΠ΅ΡΠΏΡΠ΅ΡΠΈΡΡΠ΅ΡΡΡ ΠΊΠ°ΠΊ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΠΎ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ Π°ΡΡΠΎΡΠ°Π³ΠΈΠΈ ΠΈ ΠΊΠΎΡΡΠ΅Π»ΠΈΡΡΠ΅Ρ Ρ ΡΠΈΡΠΊΠΎΠΌ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΡΡΡ ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ ΠΊΠ°ΠΊ ΠΎΠ½ΠΊΠΎΠ³Π΅Π½Π½ΠΎΠ΅ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²ΠΎ